The IL-25/ILC2 axis promotes lung cancer with a concomitant accumulation of immune-suppressive cells in tumors in humans and mice.
adoptive transfer
innate immunity
innate lymphoid cells group 2
myeloid-derived suppressor cells
non-small cell lung cancer
regulatory T lymphocytes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
22
06
2023
accepted:
21
08
2023
medline:
3
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Group 2 innate lymphoid cells (ILC2) can be activated by interleukin (IL)-33 or IL-25. IL-25-activated ILC2 cells help protect the host against helminth infection while exacerbating allergic-like inflammation and tissue damage in the lung. In the context of cancer, IL-33-activated ILC2 cells were found to bear anti-tumoral functions in lung cancer while IL-25-activated ILC2 cells promoted tumorigenesis in colorectal cancer. The role of IL-25-activated ILC2 cells in lung cancer remains to be addressed. We examined the overall survival of human non-small cell lung cancer (NSCLC) patients according to We report that human NSCLC patients with high Overall, our results indicate that the IL-25/ILC2 axis promotes lung cancer potentially by recruiting immune-suppressive cells to the tumors both in humans and in mice, and that it may therefore represent a suitable novel target for NSCLC immunotherapeutic development.
Sections du résumé
Background
Group 2 innate lymphoid cells (ILC2) can be activated by interleukin (IL)-33 or IL-25. IL-25-activated ILC2 cells help protect the host against helminth infection while exacerbating allergic-like inflammation and tissue damage in the lung. In the context of cancer, IL-33-activated ILC2 cells were found to bear anti-tumoral functions in lung cancer while IL-25-activated ILC2 cells promoted tumorigenesis in colorectal cancer. The role of IL-25-activated ILC2 cells in lung cancer remains to be addressed.
Methods
We examined the overall survival of human non-small cell lung cancer (NSCLC) patients according to
Results
We report that human NSCLC patients with high
Conclusion
Overall, our results indicate that the IL-25/ILC2 axis promotes lung cancer potentially by recruiting immune-suppressive cells to the tumors both in humans and in mice, and that it may therefore represent a suitable novel target for NSCLC immunotherapeutic development.
Identifiants
pubmed: 37781372
doi: 10.3389/fimmu.2023.1244437
pmc: PMC10540623
doi:
Substances chimiques
IL25 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1244437Informations de copyright
Copyright © 2023 Bahhar, Eş, Köse, Turna, Günlüoğlu, Çakır, Duralı and Magnusson.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Immunol. 2015 Feb;16(2):161-9
pubmed: 25531830
J Exp Med. 2017 Jun 5;214(6):1663-1678
pubmed: 28490441
MethodsX. 2020 Sep 10;7:101054
pubmed: 33005569
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Sci Rep. 2018 Feb 13;8(1):2924
pubmed: 29440650
Sci Rep. 2016 May 11;6:25643
pubmed: 27165713
Int Immunol. 2016 Jan;28(1):23-8
pubmed: 26232596
Sci Immunol. 2022 Jun 3;7(72):eabn0175
pubmed: 35658010
Nat Commun. 2015 Sep 23;6:8280
pubmed: 26395069
Nat Immunol. 2020 Sep;21(9):998-1009
pubmed: 32747815
Immunology. 2023 Apr;168(4):569-579
pubmed: 36288454
Cancers (Basel). 2021 Feb 01;13(3):
pubmed: 33535624
Protein Cell. 2017 Dec;8(12):878-895
pubmed: 28271447
Tanaffos. 2021 Jan;20(1):15-21
pubmed: 34394365
Immunity. 2014 Aug 21;41(2):283-95
pubmed: 25088770
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
pubmed: 29617574
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
J Clin Invest. 2017 Aug 1;127(8):2916-2929
pubmed: 28650339
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Mol Med Rep. 2017 Jun;15(6):4374-4381
pubmed: 28487978
Nature. 2013 Jun 6;498(7452):113-7
pubmed: 23698371
Nature. 2020 Mar;579(7797):130-135
pubmed: 32076273
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nat Commun. 2017 Sep 19;8(1):593
pubmed: 28928446
Blood Adv. 2017 Mar 30;1(10):577-589
pubmed: 29296700
Immunity. 2017 Jan 17;46(1):148-161
pubmed: 27986455
Mediators Inflamm. 2019 Jun 20;2019:3140183
pubmed: 31320835
Front Immunol. 2021 Jun 14;12:680055
pubmed: 34194433
Cell Res. 2021 May;31(5):554-568
pubmed: 33420427
Semin Immunol. 2019 Feb;41:101276
pubmed: 31130471
J Immunol. 2014 Mar 1;192(5):2442-8
pubmed: 24470502
Eur J Immunol. 2019 Sep;49(9):1421-1432
pubmed: 31144294